Evaluation of halometasone cream in the treatment of paediatric patients with acute eczematous dermatoses.
Sixty children under 10 years of age (including 18 under 3 years) suffering from non-infected acute eczematous dermatoses were treated with 0.05% halometasone cream containing a new high-potency trihalogenated synthetic dermatocorticosteroid. The trial population consisted of patients with acute atopic dermatitis, seborrhoeic dermatitis, nummular dermatitis and contact dermatitis. Halometasone cream yielded very satisfactory results and showed excellent tolerability. It produced 'good' or 'very good' results in 90% of the cases and gave an overall cure rate of 74.3%. The number of patients obtaining an early cure, i.e. in less than 20 days, was thirty-seven (62%). The onset of action was reported in 78.3% of the patients within 3 days of starting the treatment. All patients tolerated the treatment well and no adverse effects, either due to the topical application or the transcutaneous systemic absorption of the corticoid, were reported.